Merck HIV deal allows Chimerix to concentrate on other antiviral compound
This article was originally published in Scrip
Executive Summary
Merck & Co's commitment of up to $168.5 million plus royalties to develop Chimerix' CMX157 will advance the novel oral antiviral therapy for HIV and also allow privately-held Chimerix to focus its own resources on the lead compound from its proprietary lipid technology platform, CMX001, a broad-spectrum antiviral to prevent viral infections in transplant recipients.